LITESPARK-005 Archives

Copia de Copia de Copia de Banner web VHIO (1)

HIF-2α inhibitor improves outcomes in patients with previously treated advanced clear cell renal carcinoma

Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…

First-in-class HIF-2α inhibitor improves outcomes in patients with previously treated advanced clear cell renal cell carcinoma

Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…